NEW YORK, Jan. 02, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on GNMK, LNTH, ACRX, and ISRG which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com scans GenMark Diagnostics Inc. (NASDAQ: GNMK), Lantheus Holdings Inc.
Carlsbad, California headquartered GenMark Diagnostics Inc.'s shares recorded a trading volume of 333,899 shares last Friday. The stock finished the trading session 2.80% lower at $4.17. The Company's shares are trading below their 50-day moving average by 21.01%. Furthermore, shares of GenMark Diagnostics, which develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology, have a Relative Strength Index (RSI) of 34.79.
On December 21st, 2017, GenMark Diagnostics announced that President and CEO, Hany Massarany, will present at the J.P. Morgan 36th Annual Healthcare Conference in San Francisco, California. Mr. Massarany is scheduled to present on January 10th, 2017, at 3:30 p.m. PT. A live webcast of the event will be available on the Company's investor website. Get the full research report on GNMK for free by clicking below at:
On Friday, North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s stock ended the session 3.31% lower at $20.45. A total volume of 376,543 shares was traded. The Company's shares have gained 14.89% over the previous three months and 137.79% on an YTD basis. The stock is trading 18.81% above its 200-day moving average. Moreover, shares of Lantheus, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, have an RSI of 47.44.
On December 21st, 2017, Lantheus announced that Mary Anne Heino, President and CEO, and Jack Crowley, CFO, will present at the 36th Annual J.P. Morgan Healthcare Conference on January 11th, 2018, at 11:30 a.m. PT in San Francisco, California. A live webcast of the presentation will be available under the Investors section of the Company's website. The free technical report on LNTH can be accessed at:
Redwood City, California headquartered AcelRx Pharmaceuticals Inc.'s stock ended the day 3.85% higher at $2.03 with a total trading volume of 819,760 shares. The Company's shares are trading 0.04% below their 50-day moving average. Additionally, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have an RSI of 47.84. Sign up for free on Wall St. Equities and claim the latest report on ACRX at:
Shares in Sunnyvale, California headquartered Intuitive Surgical Inc. recorded a trading volume of 528,279 shares. The stock ended Friday's session 1.07% lower at $364.94. The Company's shares have gained 4.68% over the previous three months and 72.64% since the start of this year. The stock is trading above its 200-day moving average by 12.17%. Furthermore, shares of Intuitive Surgical, which designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories, have an RSI of 42.31. See the free research coverage on ISRG at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: 21 32 044 483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-medical-equipment-stocks----genmark-diagnostics-lantheus-acelrx-pharma-and-intuitive-surgical-300576337.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All